A company called Emulate is working on what it calls the Organs-on-Chips technology that will be available through lab-ready automated system called “Human Emulation System,” which could improve drug development and consumer product design. Organs-on-Chips promise greater precision and control than today’s cell-culture or animal-based experimental methods.

Emulate has just raised $28 million Series B from both existing and new investors. The former group includes Hansjörg Wyss, NanoDimension and Cedars-Sinai Medical Center, while the latter counts OS Fund, Atel Ventures, ALS Finding a Cure, and another unnamed investor. The company will use the funds to accelerate its R&D efforts, expedite the launch of its products and expand strategic relationships with industry and academic partners in order to evolve the company towards profitability.

“This financing positions Emulate to advance our Organs-on-Chips to the next stage of commercial development, so that our technology can operate as a plug-and-play system in the hands of product development teams at pharmaceutical, chemical, food, and consumer products companies,” James Coon, CEO of Emulate, said in a statement. “Based on our active R&D collaborations with industry and academic leaders, we recognize the broad potential for our Human Emulation System to help accelerate development cycles and improve products, as well as opening up new opportunities for disease understanding and personal health applications.”

The Organs-on-Chips portfolio currently includes lung, liver, intestine, and skin with additional organs such as kidney, heart, and brain coming in the future. Each of these Organ-Chips contains tiny hollow channels lined with tens of thousands of living human cells and tissues, and is approximately the size of an AA battery. An Organ-Chip is a living, micro-engineered environment that recreates the natural physiology and mechanical forces that cells experience within the human body.